• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Mereo BioPharma Group plc (Amendment)

    2/14/24 6:51:28 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MREO alert in real time by email
    SC 13G/A 1 ss3005731_sc13ga.htm AMENDMENT NO. 3
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 3)*

     

     

    Mereo BioPharma Group plc
    (Name of Issuer)

     

     

    Ordinary Shares, nominal value £0.003 per share, represented by American Depository Shares
    (Title of Class of Securities)

     

     

    589492107**
    (CUSIP Number)

     

     

    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **There is no CUSIP number assigned to the Ordinary Shares. CUSIP number 589492107 has been assigned to the American Depositary Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Stock Market under the symbol “MREO.” Each ADS represents 5 Ordinary Shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

      

       

     

    CUSIP No. 589492107  SCHEDULE 13G Page 2 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Capital GP VII LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER 

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    OO

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 589492107  SCHEDULE 13G Page 3 of 8 Pages

     

             
    1

    NAME OF REPORTING PERSONS

    OrbiMed Advisors LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 589492107  SCHEDULE 13G Page 4 of 8 Pages

     

    1

    NAME OF REPORTING PERSONS

    OrbiMed Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

    10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0.0%

    12

    TYPE OF REPORTING PERSON

    IA

             

     

     

     

     

     

       

     

     

    CUSIP No.  589492107  SCHEDULE 13G Page 5 of 8 Pages

     

    Item 1.   (a) Name of Issuer:

    Mereo BioPharma Group plc

        (b) Address of Issuer’s Principal Executive Offices:

    4th Floor, One Cavendish Place

    London, W1G 0QF, United Kingdom

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital GP VII LLC

    OrbiMed Capital LLC

    OrbiMed Advisors LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on each cover page for each Reporting Person.

        (d) Title of Class of Securities:

    Ordinary Shares, nominal value £0.003 per share, represented by American Depository Shares

        (e) CUSIP No.:

    589492107

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 589492107  SCHEDULE 13G Page 6 of 8 Pages

     

     

    Item 3.      

    OrbiMed Capital GP VII LLC (“GP VII”) is the general partner of OrbiMed Private Investments VII, LP. OrbiMed Advisors LLC (“Advisors”) and OrbiMed Capital LLC are investment advisors in accordance with ss.240.13d-1(b)(1)(ii)(E) and Advisors is the managing member of GP VII.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 589492107  SCHEDULE 13G Page 7 of 8 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2023 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9. Notice of Dissolution of Group.

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

     

     

     

     

     

     

     

     

     

       

     

     

     

    CUSIP No. 589492107  SCHEDULE 13G Page 8 of 8 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024

      OrbiMed Advisors LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member
           
      OrbiMed Capital LLC
           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

     

    OrbiMed Capital GP VII LLC

    By: OrbiMed Advisors LLC, its Managing Member

           
      By: /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member of OrbiMed Advisors LLC

     

     

     

     

     

     

     

     

    Get the next $MREO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MREO

    DatePrice TargetRatingAnalyst
    3/27/2025$7.00Overweight
    Analyst
    12/6/2024$7.00Buy
    Jefferies
    6/13/2024$8.00Outperform
    Robert W. Baird
    10/13/2023$4.00Buy
    BTIG Research
    8/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MREO
    Financials

    Live finance-specific insights

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

      LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun

      5/15/24 4:01:44 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

      LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo Bi

      3/5/25 7:30:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Yoskowitz Marc J

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:22 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bender Jeremy

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:14 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shames Daniel

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:06 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Mereo BioPharma with a new price target

      Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00

      3/27/25 8:18:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Mereo BioPharma with a new price target

      Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00

      12/6/24 7:56:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Mereo BioPharma with a new price target

      Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00

      6/13/24 7:11:27 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/15/25 10:46:23 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/14/25 4:34:46 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Group plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Mereo BioPharma Group plc (0001719714) (Filer)

      5/14/25 4:30:10 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 4:18:45 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 3:30:42 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 11:44:32 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Leadership Updates

    Live Leadership Updates

    See more
    • Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

      LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e

      5/17/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

      LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C

      3/1/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

      LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off

      9/20/21 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care